Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR.

Mol Cancer Res. 2013 Sep;11(9):1112-21. doi: 10.1158/1541-7786.MCR-13-0042. Epub 2013 Jul 3.

2.

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC.

J Clin Oncol. 2012 Jun 20;30(18):2218-26. doi: 10.1200/JCO.2011.38.5740. Epub 2012 May 14.

3.

Estrogen replacement therapy in breast cancer survivors: a matched-controlled series.

Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH.

Menopause. 2003 Jul-Aug;10(4):277-85.

PMID:
12851510
4.
5.

Impact of clinical, pathologic, and treatment-related factors on outcome in patients with locally advanced breast cancer treated with multimodality therapy.

Victor SJ, Horwitz EM, Kini VR, Martinez AA, Pettinga JE, Dmuchowski CF, Decker DA, Wilner FM, Vicini FA.

Am J Clin Oncol. 1999 Apr;22(2):119-25.

PMID:
10199443
6.

Treatment outcome with radiation therapy after breast augmentation or reconstruction in patients with primary breast carcinoma.

Victor SJ, Brown DM, Horwitz EM, Martinez AA, Kini VR, Pettinga JE, Shaheen KW, Benitez P, Chen PY, Vicini FA.

Cancer. 1998 Apr 1;82(7):1303-9.

PMID:
9529022
7.

Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations.

Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas DH.

Ann Clin Lab Sci. 1995 Jan-Feb;25(1):52-9.

PMID:
7762969

Supplemental Content

Loading ...
Support Center